GlassScriptPhysician profile
Leo H Wang
NPI 1124150156
$37,432.87
in general payments reported to CMS, 2019-2025
11 companies · $4,395 in 2025
The $4,395 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,100 · 2020: $840 · 2021: $4,975 · 2022: $3,132 · 2023: $4,810 · 2024: $17K · 2025: $4,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $23K · Travel and Lodging: $1,613 · Honoraria: $1,350 · Food and Beverage: $611 · Education: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $22,797.00 |
| Travel and Lodging | $1,612.92 |
| Honoraria | $1,350.00 |
| Food and Beverage | $610.93 |
| Education | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sarepta Therapeutics, INC. | $12,861.38 | 2022-2024 | |
| Mitsubishi Tanabe Pharma Development America, INC. | $5,750.00 | 2021-2022 | |
| Csl Behring | $4,455.54 | 2022-2025 | Hizentra |
| Argenx US, INC. | $4,423.42 | 2022-2023 | Vyvgart |
| Lupin INC. | $2,814.50 | 2024 | |
| Biogen, INC. | $2,133.33 | 2019-2022 | |
| Ucb, INC. | $1,761.37 | 2023-2025 | Zilbrysq, Rystiggo |
| Amylyx Pharmaceuticals, INC. | $1,350.00 | 2023 | Relyvrio |
| Vertex Pharmaceuticals Incorporated | $1,043.33 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $840.00 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leo Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.